Hofmann, Annika
Krajnc, Nik
Dal-Bianco, Assunta
Riedl, Christian J.
Zrzavy, Tobias
Lerma-Martin, Celia
Kasprian, Gregor
Weber, Claudia E.
Pezzini, Francesco
Leutmezer, Fritz
Rommer, Paulus
Bsteh, Gabriel
Platten, Michael
Gass, Achim
Berger, Thomas
Eisele, Philipp
Magliozzi, Roberta
Schirmer, Lucas http://orcid.org/0000-0001-7142-4116
Hametner, Simon http://orcid.org/0000-0002-5160-5208
Funding for this research was provided by:
International Progressive MS Alliance (PA-2002-36405)
Ruprecht-Karls-Universität Heidelberg
Article History
Received: 28 April 2023
Revised: 1 August 2023
Accepted: 23 August 2023
First Online: 16 September 2023
Declarations
:
: N.K. has participated in meetings sponsored by and received speaker honoraria or travel funding from BMS/Celgene, Janssen-Cilag, Merck, Novartis, Roche and Sanofi-Genzyme. A.G. received scientific funding and speaker fees from Novartis, Sanofi, Roche, Biogen, Teva, BMS. T.B. has participated in meetings sponsored by and received honoraria (lectures, advisory boards, consultations) from pharmaceutical companies marketing treatments for multiple sclerosis: Almirall, Bayer, Biogen, Biologix, Bionorica, BMS/Celgene, Eisai, GSK, Horizon, Janssen-Cilag, Jazz Pharma, MedDay, Merck, Novartis, Octapharma, Roche, Sandoz, Sanofi/Genzyme, TG Pharmaceuticals, Teva ratiopharm, and UCB. His institution has received financial support in the last 12 months by unrestricted research grants (Biogen, Bayer, BMS/Celgene, Merck, Novartis, Sanofi/Genzyme, and Teva ratiopharm) and for participation in clinical trials in multiple sclerosis sponsored by Alexion, Bayer, Biogen, Merck, Novartis, Octapharma, Roche, Sanofi/Genzyme, and Teva. L.S. filed a patent for the detection of antibodies against KIR4.1 in a subpopulation of patients with multiple sclerosis (patent application no. WO2015166057A1). S.H. received speaker honoraria from Biogen and Sanofi as well as an unrestricted research grant from Merck. All authors have nothing to declare with respect to this work.